---
title: Screen SMART
subtitle: Multi-modal prediction of major pregnancy complications
authors:
  - name: Dr Omar B Forge Risk
    affiliation: King's College London (Wellcome Trust), Imperial College London (NIHR)
    roles: Wellcome Trust CREATE Fellow \n NIHR Academic Clinical Fellow
    corresponding: Omar.Risk@kcl.ac.uk
format:
  revealjs:
    css: style.css
theme: serif
bibliography: references.bib
---

## What's the scale of the problem?

MMR per 100,000 births. Population attributable fraction of [preeclampsia]{style="color:purple;"} and [haemorrhage]{style="color:red;"}.[^1]

[^1]: @knight2025; @hollier2024; @shafiq2024

::::::::: {.columns style="text-align:center"}
:::: {.column width="33%"}
::: fragment
![](images/gb.svg){width="25%"}\
![](images/UK_MMR.svg)
:::
::::

:::: {.column width="33%"}
::: fragment
![](images/zm.svg){width="25%"}\
![](images/ZM_MMR.svg)
:::
::::

:::: {.column width="33%"}
::: fragment
![](images/sl.svg){width="25%"}\
![](images/SL_MMR.svg)
:::
::::
:::::::::

## Haemoglobin: the starting point

::::::: {.columns style="text-align:center"}
::::: {.column width="50%"}
![](images/sl.svg){width="25%"}

::: r-stack
![](images/blood1.png){width="50%"}

![](images/blood2.png){.fragment width="50%"}

![](images/blood3.png){.fragment width="50%"}
:::

::: fragment
2% routine Hb\
70% anaemic
:::
:::::

::: {.column width="50%"}
![](images/feso4.png){.fragment width="50%"}
:::
:::::::

## Preeclampsia is predictable

::::::::: {.columns style="text-align:center"}
:::: {.column width="33%"}
::: fragment
![](images/NICE.png){width="100%"}\
![](images/gb.svg){width="25%"}\
![](images/MatFac.svg){width="25%"}\
Detection rate: 40%
:::
::::

:::: {.column width="33%"}
::: fragment
![](images/papaya.png){width="50%"}\
![](images/sl.svg){width="25%"}\
![](images/MatFac.svg){width="25%"}\
Detection rate: \~5%
:::
::::

:::: {.column width="33%"}
::: fragment
![](images/FMF.png){width="100%"}\
![](images/gb.svg){width="25%"}\
![](images/MatFac.svg){width="25%"} ![](images/CRADLE.png){width="15%"}![](images/PLGF.png){width="25%"}![](images/UtA.png){width="15%"}\
Detection rate: 70%
:::
::::
:::::::::

## Preeclampsia is preventable

::::::::: {.columns style="text-align:center"}
::::: {.column width="50%"}
::: fragment
![](images/aspirin.png){width="70%"}
:::

::: fragment
![](images/sl.svg){width="25%"} ![](images/zm.svg){width="25%"}\
Uptake \~ 2%
:::
:::::

:::: {.column width="50%"}
::: fragment
![](images/aspirin_prevention.png){width="100%"}\
@rolnik2017
:::
::::

::: fragment
Early prediction enables us to target aspirin to delay severe preeclampsia and save lives.
:::
:::::::::

## Screen SMART [preeclampsia]{style="color:purple;"}

::::::::::::: {.columns style="text-align:center"}
:::: {.column width="20%"}
::: fragment
![](images/MatFac.svg)
:::
::::

:::: {.column width="20%"}
::: fragment
![](images/rapid.png){width="100%"}
:::
::::

:::: {.column width="20%"}
::: fragment
![](images/PLGF.png){width="100%"}
:::
::::

:::: {.column width="20%"}
::: fragment
![](images/GlyFn.png){width="100%"}
:::
::::

:::: {.column width="20%"}
::: fragment
![](images/POCUS.png){width="100%"}
:::
::::
:::::::::::::

::::::: {.columns style="text-align:center"}
:::: {.column width="50%"}
::: fragment
![](images/AUROC.png){width="70%"}\
:::
::::

:::: {.column width="50%"}
::: fragment
![](images/stages.png){width="70%"}\
@wright2019
:::
::::
:::::::

## Screen SMART [anaemia]{style="color:red;"}

::::::::: {.columns style="text-align:center"}
:::: {.column width="25%"}
::: fragment
![](images/rapid.png){width="100%"}\
Shock index
:::
::::

:::: {.column width="25%"}
::: fragment
![](images/gazelle.png){width="100%"}\
Fe\
HbSS\
Î²-thal
:::
::::

:::: {.column width="25%"}
::: fragment
![](images/who-colour.png){width="60%"}\
Digital anaemia colour scale
:::
::::

:::: {.column width="25%"}
::: fragment
![](images/POCHb.png){width="40%"}\
POC Hb
:::
::::
:::::::::

## Study

::::::::: {.columns style="font-size: 65%"}
:::: {.column width="50%"}
::: fragment
**Population**

-   n = 10,000

-   Unselected early pregnancy cohort

-   EGA \< 20/40

-   Singleton pregnancy

-   Age 16+
:::
::::

:::::: {.column width="50%"}
::::: fragment
**Sites & Facilities**

::: {.column width="50%" style="text-align:center"}
![](images/sl.svg){width="25%"}\
n = 5,000\
3 hospital\
40 community
:::

::: {.column width="50%" style="text-align:center"}
![](images/zm.svg){width="25%"}\
n = 5,000\
4 hospital\
42 community
:::
:::::
::::::
:::::::::

::::::: {.columns style="font-size: 65%"}
:::: {.column width="50%"}
::: fragment
**Aims**: Screen SMART [**anaemia**]{style="color:red;"}

-   Product development

-   Test validation

-   Implementation potential
:::
::::

:::: {.column width="50%"}
::: fragment
**Aims**: Screen SMART [**preeclampsia**]{style="color:purple;"}

-   Product development

-   Test validation

-   Feasible & accurate, prediciton
:::
::::
:::::::

## Acknowledgements

Supervisors:

-   **Dr Antonio de Marvao**

-   Prof Bellington Vwalika

-   Dr Kate Bramham

-   Dr Alex Ridout

-   Prof Andrew Shennan
<div style="height:1.2rem"></div>
::::::::::::: {.columns style="text-align:center"}
:::: {.column width="20%"}
![](images/KCL.png)
::::
:::: {.column width="20%"}
![](images/UnZa.svg)
::::
:::: {.column width="20%"}
![](images/zambart.png)
::::
:::: {.column width="20%"}
![](images/CREATE.png)
::::
:::: {.column width="20%"}
![](images/NIHR.png)
::::
:::::::::::::

## References